Based in Pennsylvania, privately held Greene Street Pharmaceuticals develops and manufactures transdermal medicines, taking products from formulation through clinical studies and commercialization in-house. Its distinctive model combines a portfolio of Transdermal Innovative Products with small-scale direct manufacturing capacity of more than 3 million patches annually, focused on the 505(b)(2) pathway and on delivery options for patients with swallowing difficulties. The company operates an FDA-registered facility capable of production under cGMP standards.
FDA Registered Facility
registration
cGMP Standards
compliance_program